Physician profile
Mark A Portacci
NPI 1265500490
$6,568.46
in general payments reported to CMS, 2019-2025
40 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $786 · 2021: $1,471 · 2022: $1,140 · 2023: $674 · 2024: $636 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.45 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,191.78 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,123.65 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $591.34 | 2020-2025 | |
| Novo Nordisk INC | $517.31 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $410.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $314.89 | 2019-2023 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $274.13 | 2024-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $261.30 | 2019-2023 | Verquvo |
| Avanir Pharmaceuticals, INC. | $201.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $196.82 | 2020-2022 | |
| Pfizer INC. | $193.95 | 2019-2025 | |
| Astellas Pharma US INC | $154.56 | 2020-2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $124.09 | 2019-2024 | |
| Esperion Therapeutics, INC. | $118.42 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $116.67 | 2022-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Portacci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.